Close menu




November 20th, 2026 | 05:55 CET

Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

  • Biotechnology
Photo credits: ChatGPT KI generiert

Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BioNxt Solutions Inc | CA0909741062 , CH0012005267 , DE0006599905

Table of contents:


    Merck KGaA – The billion-euro drug faces competition

    A successful medicine can generate high profits for years. But as soon as patent protection weakens, the unpleasant part of the business often begins for pharmaceutical companies. At Darmstadt-based Merck KGaA, this is currently evident with the multiple sclerosis medicine Mavenclad. The active ingredient cladribine has become established as a treatment for certain relapsing forms of the disease. In the US, generic competition is now increasingly emerging.

    The consequences have already been factored into the forecast. As a precaution, Merck expects no further US sales of Mavenclad for November and December. At the same time, the rest of the business is performing better than expected. Last week, the group raised its full-year forecast for the third time this year.

    In the third quarter, revenue rose 5.8% to EUR 5.6 billion. Adjusted EBITDA reached EUR 1.7 billion. For the full year, management now expects revenue of between EUR 21.5 billion and EUR 21.9 billion and EBITDA before exceptional items of EUR 6.2 billion to EUR 6.4 billion.

    The Life Science and Electronics divisions in particular are delivering growth. This enables Merck to partly offset pressures on its pharmaceutical business.

    Analysts remain cautious despite the raised forecast. Jefferies maintained its Hold rating with a price target of EUR 144. UBS also maintained its Neutral or Hold rating and a target of EUR 150. Bernstein, by contrast, raised its price target from EUR 151 to EUR 178, but maintained its Neutral rating.

    BioNxt Solutions – Patent success and the next step towards clinical trials

    A proven active ingredient, but a new dosage form. BioNxt Solutions aims to simplify the treatment of multiple sclerosis. The Canadian biotechnology developer is working on BNT23001, a thin, cladribine oral dissolvable film (ODF) that dissolves under the tongue. This could make administration significantly easier, particularly for patients with swallowing difficulties.

    Cladribine is already approved as the active ingredient in Merck's MS medicine Mavenclad. BioNxt is developing an independent formulation intended to enable comparable absorption of the active ingredient. There is no collaboration with Merck.

    In October, the company reached two important milestones. Around 1,500 trial films were manufactured under GMP conditions. This was followed on October 16 by the submission of the European clinical trial application. BioNxt had already completed the required investigational medicinal product dossier in August.

    The planned trial in healthy adults is intended to investigate whether BNT23001 is comparable to Mavenclad in terms of active ingredient absorption and bioequivalence. Earlier preclinical studies provided supporting results. Regulatory approval and the final release of the trial films are still pending.

    Another positive is patent protection. Since March 2026, BioNxt has held a European unitary patent effective in 18 EU countries, including Germany and France, for its cladribine ODF technology.

    For the next development steps, BioNxt announced a private placement of up to CAD 2.5 million. Plans envisage 10 million units at CAD 0.25, each consisting of one share and one warrant.

    With GMP manufacturing complete, the clinical trial application submitted, and the European patent granted, BioNxt has met key prerequisites for further clinical development.

    Watch YouTube video

    Novartis – New trial data increase the pressure

    While Merck is battling generic competition and BioNxt is developing an alternative cladribine formulation, Novartis is already working on the next generation of MS therapies. The Swiss pharmaceutical group has an established medicine in Kesimpta and could add another active ingredient to its portfolio in future.

    The focus is on remibrutinib. The oral BTK inhibitor has delivered positive results in two Phase III trials for relapsing multiple sclerosis. Compared with the comparator medicine teriflunomide, the active ingredient significantly reduced the annualised relapse rate. MRI scans also showed lower disease activity.

    According to the company, more than 92% of treated patients remained free of confirmed disability progression at 6 months during the period studied. However, a statistically significant advantage for this endpoint was not demonstrated in all analyses. Regulatory approval is also still pending.

    Kesimpta demonstrates that the MS market is already a significant business for Novartis. In the third quarter, sales of the medicine rose by 22% at constant currencies.

    The group as a whole is also growing. Quarterly revenue rose 4% at constant currencies, while adjusted operating profit increased 10%. The corresponding full-year profit forecast was raised. However, an impairment charge on another development project weighed on results.

    Novartis thus has a combination of existing revenue and advanced research. The positive remibrutinib data could strengthen its competitive position in the MS market, provided the active ingredient is approved.

    Conclusion

    Merck must manage the generic pressure on Mavenclad, but can draw on a broadly diversified business. BioNxt Solutions is attempting to find its own place in the market with a new cladribine dosage form. Novartis is relying on growing sales of Kesimpta and new active ingredients such as remibrutinib. While the major pharmaceutical groups are already earning billions, BioNxt still faces crucial clinical trials.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Stefan Feulner on October 22nd, 2026 | 05:25 CEST

    BioNTech, Formycon, Biogen: Pharma billions are being redistributed

    • Biotechnology

    The pharmaceutical industry is facing a massive restructuring. As blockbuster drugs worth billions lose patent exclusivity, cheaper copycat products are entering the market. At the same time, biotech groups are investing billions in new cancer drugs and therapies for diseases that have long been difficult to treat. For investors, this creates tension between established revenue generators, new active ingredients and rising healthcare costs. Companies that secure access to lucrative drug markets early are particularly interesting. Even a small share of a global blockbuster's revenue can have considerable economic significance.

    Read

    Commented by Stefan Feulner on October 21st, 2026 | 05:38 CEST

    Regeneron, Vidac Pharma, Krystal Biotech: New Active Ingredients, Enormous Stock Market Potential

    • Biotechnology

    Cancer treatment is undergoing a fundamental transformation. Rather than relying solely on conventional chemotherapy, new approaches increasingly target the biological mechanisms that drive tumours. In particular, immunotherapies, gene therapies and interventions targeting cellular metabolism are opening up new possibilities for treating skin cancer. As approved medicines reach more patients, innovative biotech companies face key clinical milestones. Commercial opportunities are substantial, as demand for effective, well-tolerated treatments continues to grow. The decisive factor will be which technologies can confirm their promising results in larger clinical trials.

    Read

    Commented by Stefan Feulner on October 20th, 2026 | 05:23 CEST

    AstraZeneca, Cardiol Therapeutics, Kiniksa – New hope for heart patients

    • Biotechnology

    Cardiovascular diseases remain among the greatest medical challenges worldwide. While established pharmaceutical groups invest billions in new active ingredients and artificial intelligence, specialised biotech companies are developing targeted therapies for conditions that have so far been difficult to treat, such as recurrent pericarditis. Patients often suffer from painful relapses and require long-term treatment. New medicines could fundamentally change how these conditions are managed. For investors, this brings into focus companies that already market approved products or are awaiting pivotal clinical trial results.

    Read